Navigation Links
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
Date:6/18/2013


 - Basic[1] and Diluted (RMB/US$)

0.40 

0.32

 

0.051.79 

1.49

 

0.24Revenue Breakdown (%)Processing Fees

74.0%72.2%74.0%75.4%Storage Fees

26.0%27.8%26.0%24.6%New Subscribers (persons)

14,33616,05953,92472,228Total Accumulated Subscribers (persons)

239,754311,982239,754311,982Summary – Selected Cash Flow Statement ItemsThree Months EndedYear EndedMarch 31, 2013March 31, 2013(in thousands)

RMB

US$RMB

US$Net cash provided by operating activities

155,079

24,969578,632

93,166Net cash used in investing activities

(137,297)

(22,106)(493,717)

(79,494)Net cash (used in)/provided by financing activities

(2,750)

(443)618,718

99,620Fourth Quarter of Fiscal 2013 Financial ResultsREVENUES.  Revenues increased by 33.3% to RMB133.0 million ($21.4 million) in the fourth quarter of fiscal 2013 from RMB99.8 million in the prior year period, driven by increasing new subscriber sign-ups during the quarter, as well as the strong increase in recurring income from our rising accumulated subscriber base.Revenues generated from storage fees increased to RMB37.0 million ($6.0 million), up 42.3% from RMB26.0 million in the prior year period.  As a result of the expanded subscriber base, revenue generated from storage fees as a percentage of total revenues increased to approximately 27.8%, from 26.0% in the prior year period.Revenues generated from processing fees increased to RMB96.0 million ($15.4 million) due to the increase in new subscribers sign-ups.  Revenues generated from processing fees accounted for 72.2% of total revenues, compared to 74.0% in the prior year period.

GROSS PROFIT.  Gross profit for the fourth quarter of fiscal 2013 increased by 38.8% to RMB106.1 million ($17.1 million) with gross margin expanded f
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. RAPS Opens Offices in Singapore and China
2. Research Report on Chinas Diabetes Drug Market, 2013-2017
3. Research Report on Chinas Antidepressant Market, 2013-2017
4. Research Report on Chinas Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
5. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
6. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
7. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
8. China Engineering Plastics Industry will Reach US$5 Million By 2017 - Engineering Plastics Market, Share, Size, Analysis, Market Scale, Competition and Forecast 2013-2017
9. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
10. Future Course of New Lethal Avian Flu Outbreak in China Can Be Predicted
11. China Cord Blood Corporation Received AABB Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... system (Nexera UC) can sequentially analyze up to ... combined with high-sensitivity detection of targets by mass ... designed to fulfill the measurement requirements of a ... food products, drug delivery and search for disease ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
(Date:2/27/2015)... PureTech , a science and technology R&D company focused  ... in the healthcare sector, announced today the appointment of ... the Board of Directors of Sanofi, to its Board ... pleasure to know Chris for many years and I ... more closely now," said Dr. Robert Langer , ...
(Date:2/26/2015)...  23andMe, the leading personal genetics company, today announced ... Officer and Corporate Counsel. Black brings a strong background ... as health care regulations. As a member of the ... reviewing, updating and enhancing the company,s privacy and consent ... joined the company January 5, 2015 and reports to ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 423andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... it Possible for Employers to Hire Overseas Workers - ... Today,s outsourcing industry has taken a giant leap forward ... Systems ( http://www.cybracero.com ), which makes it possible ... the first-world countries without ever having to leave their ...
... for Samtheo,s Personalized Medicine PortfolioNEW YORK, March 16 ... license agreement, through its subsidiary, Lyndor Biosciences LLC, ... to a small molecule that selectively inhibits the ... activation of the Akt pathway has been found ...
... Call to be Held at 9:00 a.m. Eastern Time ... 16 United Therapeutics Corporation (Nasdaq: UTHR ... interactions with the U.S. Food and Drug Administration (FDA), ... Application (NDA) for Tyvaso(TM) (inhaled treprostinil) will likely extend ...
Cached Biology Technology:New Technology to Revolutionize the Way the Planet Does Business 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 3United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 2United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 3
(Date:2/5/2015)... , Jan. 28, 2015 Research and ... the addition of the "Global Biometrics Market ... Regions and Countries " report to their offering. ... Asia-Pacific is anticipated to ... 2015, owing to increasing government spending towards IT ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Elderly mice suffering from age-related heart disease saw a significant ... drug rapamycin for just three months. The research, led ... Research on Aging, shows how rapamycin impacts mammalian tissues, providing ... been shown to extend the lifespan of mice as much ...
... Scientists at Rice University and Oak Ridge National Laboratory ... a method to control the growth of uniform atomic layers ... of a trilogy of materials needed to make functioning 2-D ... manufacture of devices so small they would be invisible to ...
... part of the skeletal support for the membrane in ... Joanny from the Physico Chemistry Curie Unit at the ... a well-defined layer beneath the cell outer membrane forms ... motor proteins within the cellular system. These findings, which ...
Cached Biology News:Lifespan-extending drug given late in life reverses age-related heart disease in mice 22-D electronics take a step forward 22-D electronics take a step forward 3
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
Biology Products: